BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Study Overview

The purpose of this study is to study two US FDA approved drugs alone and in combination with each other in people who have mCRPC and DNA repair defects.

Study Description

This is a prospective, 4 arm, multicenter, randomized, Phase II study in subjects with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects. This study will evaluate the use of two US FDA approved drugs alone and in combination with each other in people who have mCRPC and DNA repair defects. The primary objective is to evaluate the objective PFS of abiraterone/prednisone, olaparib or the combination abiraterone/prednisone + olaparib in mCRPC patients with canonical DNA repair defects in BRCA1,BRCA2, or ATM.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1708862929 (C16-168)
  • Research Study Identifier: TX8334
  • Principal Investigator: Roberto Pili, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176